Know When to Consider New COVID-19 Monoclonal Antibodies

January 2021

Bamlanivimab and casirivimab/imdevimab will be the first meds authorized to treat OUTPATIENTS with COVID-19.

These new monoclonal antibodies block SARS-CoV-2 from entering cells. Both meds are single-dose IV infusions given over 1 hour.

They’re being given at many locations, such as infusion centers...pop-up sites (tents, etc)...long-term care...or even patients’ homes.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote